HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.

AbstractPURPOSE:
The aim of this study was to compare the effects of fibrates and omega-3 fatty acids on lymphocyte secretory function and systemic inflammation in patients with isolated hypertriglyceridemia.
METHODS:
The study included 107 patients with isolated hypertriglyceridemia who received bezafibrate (200 mg twice daily), omega-3 fatty acids (1 g twice daily) or placebo for 12 weeks. The lipid profile, fasting and 2-h post-glucose load plasma glucose levels, homeostasis model assessment index (HOMA), plasma high-sensitivity C-reactive protein (hsCRP) levels and lymphocyte release of interleukin-2, interferon-γ and tumor necrosis factor-α were assessed at baseline, on the day of randomization, and after 4 and 12 weeks of treatment.
RESULTS:
Both bezafibrate and omega-3 fatty acids reduced plasma triglyceride levels. Bezafibrate additionally decreased total and low-density lipoprotein-cholesterol levels and the HOMA and insignificantly decreased post-glucose load plasma glucose, as well as increased high-density lipoprotein-cholesterol. Bezafibrate treatment was associated with a reduction in lymphocyte release of interleukin-2, interferon-γ and tumor necrosis factor-α, which was accompanied by a reduction in plasma hsCRP levels. Omega-3 fatty acid did not significantly reduce lymphocyte cytokine release and plasma hsCRP. The anti-inflammatory effects of both drugs did not correlate with their action on plasma lipids, but in the case of the former the effect was related to the improvement in insulin sensitivity.
CONCLUSION:
Our results indicate that bezafibrate is superior to omega-3 fatty acid in inhibiting systemic inflammation and lymphocyte secretory function.
AuthorsRobert Krysiak, Anna Gdula-Dymek, Boguslaw Okopien
JournalEuropean journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 67 Issue 11 Pg. 1109-17 (Nov 2011) ISSN: 1432-1041 [Electronic] Germany
PMID21630032 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Cytokines
  • Fatty Acids, Omega-3
  • Hypolipidemic Agents
  • Triglycerides
  • C-Reactive Protein
  • Cholesterol
  • Bezafibrate
Topics
  • Adult
  • Aged
  • Bezafibrate (administration & dosage, adverse effects, therapeutic use)
  • C-Reactive Protein (metabolism)
  • Cholesterol (blood)
  • Cytokines (metabolism)
  • Fatty Acids, Omega-3 (administration & dosage, adverse effects, therapeutic use)
  • Female
  • Humans
  • Hypertriglyceridemia (blood, drug therapy, immunology)
  • Hypolipidemic Agents (administration & dosage, adverse effects, therapeutic use)
  • Inflammation (blood, immunology)
  • Lymphocytes (drug effects, immunology, metabolism)
  • Male
  • Middle Aged
  • Treatment Outcome
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: